12 years of revenue, profit, cash flow and balance-sheet history through FY2025, from SEC filings — with a computed, factual read of the trend. Updated Overview →
| FY | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| 2025 | $4M | -$582M | 0.0% | -18933.6% | -$346M | $0 | $348M |
| 2024 | $37M | -$366M | 0.0% | -1250.4% | -$145M | — | $298M |
| 2023 | $371M | -$154M | 0.0% | -60.0% | -$270M | — | $389M |
| 2022 | $1M | -$650M | 0.0% | -56190.4% | -$533M | — | $212M |
| 2021 | $915M | $378M | 0.0% | 40.8% | $457M | — | $923M |
| 2020 | $719000 | -$349M | 0.0% | -49295.5% | -$257M | — | $1.2B |
| 2019 | $290M | $67M | 0.0% | 16.1% | $50M | — | $944M |
| 2018 | $3M | -$165M | 0.0% | -5087.8% | -$99M | — | $457M |
| 2017 | — | -$68M | — | — | -$78M | — | $240M |
| 2016 | — | -$23M | — | — | -$56M | — | $316M |
| 2015 | — | -$26M | — | — | — | — | $156M |
| 2014 | — | -$7M | — | — | — | — | $945000 |
| Quarter | Revenue | Net income | Gross M | Op M | FCF | Total debt | Cash |
|---|---|---|---|---|---|---|---|
| Mar '26 | $1M | -$123M | 0.0% | -8933.3% | -$109M | $585M | $423M |
| Dec '25 | $864000 | -$131M | 0.0% | -17912.5% | -$93M | $0 | $348M |
| Sep '25 | $889000 | -$106M | 0.0% | -14854.8% | -$85M | — | $286M |
| Jun '25 | $892000 | -$209M | 0.0% | -25709.0% | -$114M | — | $194M |
| Mar '25 | $865000 | -$136M | 0.0% | -17158.8% | -$54M | — | $235M |
| Dec '24 | $36M | -$37M | 0.0% | -181.0% | -$50M | — | $298M |
| Sep '24 | $602000 | -$86M | 0.0% | -18294.0% | -$107M | — | $226M |
| Jun '24 | $517000 | -$126M | 0.0% | -29257.3% | -$96M | — | $484M |
| Mar '24 | $504000 | -$117M | 0.0% | -27894.2% | $109M | — | $707M |
| Dec '23 | $201M | $89M | 0.0% | 34.6% | -$97M | — | $389M |
| Sep '23 | $0 | -$112M | — | — | -$42M | — | $528M |
| Jun '23 | $70M | -$78M | 0.0% | -136.0% | -$137M | — | $445M |
| Mar '23 | $100M | -$53M | 0.0% | -64.5% | $6M | — | $344M |
| Dec '22 | $6000 | -$111M | 0.0% | -2192350.0% | -$382M | — | $212M |
| Sep '22 | $94000 | -$175M | 0.0% | -194029.8% | $152M | — | $494M |
| Jun '22 | $158000 | -$186M | 0.0% | -115987.3% | -$152M | — | $497M |
| Mar '22 | $940000 | -$179M | 0.0% | -18720.4% | -$151M | — | $684M |
| Dec '21 | $13M | -$141M | 0.0% | -1129.5% | -$95M | — | $923M |
| Sep '21 | $824000 | -$127M | 0.0% | -15637.0% | -$118M | — | $1.0B |
| Jun '21 | $901M | $759M | 0.0% | 84.7% | $779M | — | $1.6B |
How the market has priced CRSP against its own fundamentals since 2023-03 — each month-end's share price set against the most recent annual filing, so the multiple moves as price runs ahead of (or behind) earnings. Split-adjusted.
Over the past 5 years, Crispr Therapeutics Ag's revenue has grown 37.3% per year. These are computed facts, not advice.
As of FY2025, Crispr Therapeutics Ag reported $0 of total debt against $348M of cash.
In FY2025, gross margin was —, operating margin -18933.6%, and net margin -16569.8%.
All figures are extracted from the company’s SEC EDGAR/XBRL filings — 10-K annual reports and 10-Q quarterly reports (use the Annual / Quarterly toggle). Quarterly figures are derived from the as-filed statements (year-to-date amounts are differenced into discrete quarters). Growth rates and ratios are computed by tradmap; nothing here is investment advice.
Source: SEC EDGAR / XBRL (10-K + 10-Q filings) · prices EOD (Databento), corporate-action-adjusted · growth rates, valuation multiples & ratios computed by tradmap. Valuation uses each month-end price against the latest annual filing. Informational only — not investment advice.